# CJC-1295 Ipamorelin Dosage in Research: Doses Studied, Half-Lives, Routes

> CJC-1295 Ipamorelin dosage as it appears in the research literature — the doses administered to which species by which route, plus half-life and handling context. No human dosing.

Research-context doses and half-lives for each half, with the DAC-versus-no-DAC timing kept explicit.

## Read this first

This page describes how **CJC-1295 Ipamorelin** dosing appears *in the published research* — which doses were given to which animals or volunteers, by which route, and how long each peptide lasts in the blood. It is not a how-to and carries no human protocol. Two things make a single 'dose' impossible to state honestly here: first, the fixed mixed pair has never been through a dosing trial, so there is no studied dose for the combination itself; second, the two halves run on wildly different clocks — the long-acting CJC-1295 (DAC) lingers for days while ipamorelin clears in hours. Everything below is reported in the third person, attributed to a study and a species, with no instruction to anyone. Numbers are written as 'studied at X in [species] by [route]', never as a recommendation.

## Cjc 1295 ipamorelin dosage

There is no validated human **cjc 1295 ipamorelin dosage** for the fixed combination — no controlled trial has ever dosed the pre-mixed pair, so any single figure would be an extrapolation, not a finding. What the literature *does* provide is single-component dosing. For CJC-1295 (with DAC), human Phase 1 pharmacokinetic studies administered 30 to 90 µg/kg subcutaneously [1], and GHRH-knockout mouse work used 2 µg/day [7]. For ipamorelin, rodent studies used figures such as 100 µg/kg three times daily for bone endpoints and 0.01 to 1 mg/kg intravenously for gut-motility models, with around 1 µg/kg plateauing the GH response in rodents [2][8]; no validated human pharmacokinetic dose for ipamorelin has been published. Those are research observations in named species, not a template for use.

## Half-lives — the part that matters most

The half-life split is the single most important number set here. CJC-1295 *with DAC* runs about six to eight days in humans, because the albumin-bound peptide is detectable in rat plasma beyond 72 hours and clears slowly [1][5]. CJC-1295 *no-DAC* — Mod GRF (1-29) — is the opposite: on the order of minutes to roughly 30 minutes, like native GRF(1-29), because DPP-IV cleaves it fast [5]. Ipamorelin sits under about two hours in rodent plasma, with the peak GH response near 40 minutes post-dose; no validated human half-life has been published [2]. Pairing a multi-day agent with a sub-two-hour one is exactly why the combination's net GH exposure is uncharacterized for any specific schedule.

## Routes and handling, as studied

Across the literature the routes studied are subcutaneous and intravenous, with continuous subcutaneous infusion (osmotic minipump) and intranasal delivery used in rodent pharmacokinetic work [1][2]. On handling: lyophilised (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative), aqueous peptide solutions are kept refrigerated at 2–8 °C and degrade over weeks via asparagine deamidation, with degradation products that can be markedly less potent; agitation and repeated freeze-thaw are avoided. GHRH analogues face DPP-IV cleavage in plasma, which is exactly what CJC-1295's substitutions and DAC were engineered to resist [5]. This is standard laboratory-handling context only — not an instruction to prepare or administer anything.

## Why no human number appears here

It would be easy to print a 'typical' figure; it would not be honest. The fixed **CJC-1295 Ipamorelin** combination has never been dosed in a controlled human trial, and ipamorelin has no published human pharmacokinetic dose at all. The CJC-1295 human numbers that *do* exist come from Phase 1 pharmacokinetic studies designed to characterize the molecule's behavior, not to establish a use protocol [1]. So the responsible thing — and the line this site holds — is to report what was studied, in which species, by which route, and to stop there. For the safety reasoning behind that caution, see [the effects page](/effects).

---

A bright, fully-cited read of the CJC-1295 and ipamorelin literature — two emission lines, one honest gap where the fixed blend's trial should be; no clinic on the bench and nothing here dosed, mixed, prescribed, or sold.